TET2 and Familial prostate cancer: While most genes exhibit low methylation (98% with β-values < 0.5; Figure S4), distinct hypermethylation events were observed: PABPN1 and CTU1 show pan-cancer hypermethylation, whereas TET2 display cancer-specific hypermethylation in PRAD (Figure 1F), aligning with prior evidence implicating TET2 methylation as a potential biomarker for prostate cancer progression [41].